[11 June 2013]
Products Affected - Description
Vibativ Injection, Astellas
250 mg vial, 10 count (NDC 00469-3525-30)
750 mg vial, 10 count (NDC 00469-3575-50)
Reason for the Shortage
- Astellas was the sole manufacturer of telavancin injection.
- In November 2011, Astellas placed a hold on telavancin and other products manufactured by a third party during ongoing investigations of production equipment and processes.
- In January 2012, Astellas announced the termination of its telavancin development and commercialization agreement with Theravance. Astellas has ceased promotional marketing of telavancin. Astellas will temporarily provide support for the product while Theravance examines other commercialization routes.
Available Products
No products are available.
Estimated Resupply Dates
Vibativ injection is not available at this time and the company cannot estimate a release date. No emergency supplies are available.
Related Shortages
Updated
June 11, 2013; April 29, 2013; March 15, 2013; January 11, 2013; November 13, 2012; September 4, 2012; June 4, 2012; April 10, 2012; February 24, 2012; January 20, 2012, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
Disclaimer
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins